AU2001243346A1 - Antisense modulation of e2f transcription factor 1 expression - Google Patents
Antisense modulation of e2f transcription factor 1 expressionInfo
- Publication number
- AU2001243346A1 AU2001243346A1 AU2001243346A AU4334601A AU2001243346A1 AU 2001243346 A1 AU2001243346 A1 AU 2001243346A1 AU 2001243346 A AU2001243346 A AU 2001243346A AU 4334601 A AU4334601 A AU 4334601A AU 2001243346 A1 AU2001243346 A1 AU 2001243346A1
- Authority
- AU
- Australia
- Prior art keywords
- expression
- transcription factor
- antisense modulation
- antisense
- modulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000015699 E2F1 Transcription Factor Human genes 0.000 title 1
- 108010063774 E2F1 Transcription Factor Proteins 0.000 title 1
- 230000000692 anti-sense effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/517,584 US6187587B1 (en) | 2000-03-02 | 2000-03-02 | Antisense inhibition of e2f transcription factor 1 expression |
US09517584 | 2000-03-02 | ||
PCT/US2001/006544 WO2001064706A1 (en) | 2000-03-02 | 2001-03-01 | Antisense modulation of e2f transcription factor 1 expression |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001243346A1 true AU2001243346A1 (en) | 2001-09-12 |
Family
ID=24060398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001243346A Abandoned AU2001243346A1 (en) | 2000-03-02 | 2001-03-01 | Antisense modulation of e2f transcription factor 1 expression |
Country Status (5)
Country | Link |
---|---|
US (1) | US6187587B1 (en) |
EP (1) | EP1268507A4 (en) |
JP (1) | JP2003525058A (en) |
AU (1) | AU2001243346A1 (en) |
WO (1) | WO2001064706A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0950097A2 (en) | 1996-12-27 | 1999-10-20 | Instituto de Investigaciones Bioquimicas Fundacion Campomar | Compositions and methods for tumour therapy |
US20030087854A1 (en) * | 2001-09-10 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of fibroblast growth factor receptor 3 expression |
US6444464B1 (en) * | 2000-09-08 | 2002-09-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of E2F transcription factor 2 expression |
PT1402073E (en) * | 2001-06-05 | 2007-05-31 | Auckland Uniservices Ltd | Methods and compositions for assessment of pulmonary function and disorders |
CA2449517A1 (en) * | 2001-06-08 | 2002-12-19 | Utah Ventures Ii, L.P. | Tissue-specific endothelial membrane proteins |
US20040048818A1 (en) * | 2001-09-07 | 2004-03-11 | Ian Popoff | Antisense modulation of e2f transcription factor 2 expression |
WO2003050133A1 (en) * | 2001-12-07 | 2003-06-19 | Isis Pharmaceuticals, Inc. | Antisense modulation of estrogen receptor beta expression |
US7968762B2 (en) * | 2004-07-13 | 2011-06-28 | Van Andel Research Institute | Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF) |
US20060069055A1 (en) * | 2004-09-21 | 2006-03-30 | Maya Dajee | Delivery of polynucleotides |
CA2608142A1 (en) * | 2005-05-10 | 2006-11-16 | Synergenz Bioscience Limited | Methods and compositions for assessment of pulmonary function and disorders |
AU2006248201A1 (en) * | 2005-05-19 | 2006-11-23 | Synergenz Bioscience Limited | Methods for the assesssment of risk of developing lung cancer using analysis of genetic polymorphisms |
US7933722B2 (en) * | 2005-05-20 | 2011-04-26 | Synergenz Bioscience Limited | Methods of analysis of polymorphisms and uses thereof |
WO2009043959A1 (en) * | 2007-10-03 | 2009-04-09 | Consejo Superior De Investigaciones Cientificas | Method for identifying patients with sporadic burkitt's lymphoma, identification method and use of compounds for the treatment of sporadic burkitt's lymphoma |
EP2350264A4 (en) | 2008-11-06 | 2012-08-29 | Univ Johns Hopkins | Treatment of chronic inflammatory respiratory disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5759803A (en) | 1992-05-13 | 1998-06-02 | Dana-Farber Cancer Institute | Recombinant retinoblastoma-associated protein 1 (E2F-1) polypeptides and cDNA |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
WO1995024223A1 (en) | 1994-03-08 | 1995-09-14 | Thomas Jefferson University | Inhibition of cell proliferation by e2f-1 antisense oligonucleotides |
-
2000
- 2000-03-02 US US09/517,584 patent/US6187587B1/en not_active Expired - Lifetime
-
2001
- 2001-03-01 EP EP01916307A patent/EP1268507A4/en not_active Withdrawn
- 2001-03-01 WO PCT/US2001/006544 patent/WO2001064706A1/en not_active Application Discontinuation
- 2001-03-01 JP JP2001564199A patent/JP2003525058A/en active Pending
- 2001-03-01 AU AU2001243346A patent/AU2001243346A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001064706A1 (en) | 2001-09-07 |
EP1268507A4 (en) | 2003-09-24 |
US6187587B1 (en) | 2001-02-13 |
EP1268507A1 (en) | 2003-01-02 |
JP2003525058A (en) | 2003-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001290697A1 (en) | Antisense modulation of e2f transcription factor 2 expression | |
AU2001289085A1 (en) | Antisense modulation of flip-c expression | |
AU2212600A (en) | Antisense modulation of g-alpha-i1 expression | |
AU6296099A (en) | Antisense modulation of g-alpha-12 expression | |
AU2002309819A1 (en) | Antisense modulation of PTP1B expression | |
AU2002227435A1 (en) | Antisense modulation of calreticulin expression | |
AU2001294926A1 (en) | Antisense modulation of smad6 expression | |
AU2001229493A1 (en) | Antisense modulation of mekk2 expression | |
AU2001277054A1 (en) | Antisense modulation of lysophospholipase i expression | |
AU3868699A (en) | Antisense modulation of rhoa expression | |
AU2001229447A1 (en) | Antisense modulation of smad7 expression | |
AU2001278077A1 (en) | Antisense modulation of ptp1b expression | |
AU2001261808A1 (en) | Antisense modulation of pten expression | |
AU2001243346A1 (en) | Antisense modulation of e2f transcription factor 1 expression | |
AU6115400A (en) | Antisense modulation of mekk5 expression | |
AU2001227847A1 (en) | Antisense modulation of pepck-cytosolic expression | |
AU5321199A (en) | Antisense modulation of inhibitor-kappa b kinase-beta expression | |
AU5222899A (en) | Antisense modulation of inhibitor-kappa b kinase-alpha expression | |
AU2001283443A1 (en) | Antisense modulation of hpk/gck-like kinase expression | |
AU2001257220A1 (en) | Antisense modulation of inhibitor of dna binding-1 expression | |
AU2209000A (en) | Antisense modulation of pepck-mitochondrial expression | |
AU2002230869A1 (en) | Antisense modulation of hepsin expression | |
AU5486700A (en) | Antisense modulation of g-alpha-s1 expression | |
AU2002226064A1 (en) | Antisense modulation of talin expression | |
AU2001287136A1 (en) | Antisense modulation of glioma-associated oncogene-1 expression |